• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

高剂量雷贝拉唑和阿莫西林联合治疗与雷贝拉唑、阿莫西林和甲硝唑三联疗法作为标准三联疗法后幽门螺杆菌感染的挽救方案。

Dual therapy with high doses of rabeprazole and amoxicillin versus triple therapy with rabeprazole, amoxicillin, and metronidazole as a rescue regimen for Helicobacter pylori infection after the standard triple therapy.

作者信息

Shirai Naohito, Sugimoto Mitsushige, Kodaira Chise, Nishino Masafumi, Ikuma Mutsuhiro, Kajimura Masayoshi, Ohashi Kyoichi, Ishizaki Takashi, Hishida Akira, Furuta Takahisa

机构信息

Department of Laboratory Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan.

出版信息

Eur J Clin Pharmacol. 2007 Aug;63(8):743-9. doi: 10.1007/s00228-007-0302-8. Epub 2007 Jun 13.

DOI:10.1007/s00228-007-0302-8
PMID:17565490
Abstract

BACKGROUNDS AND AIMS

Development of safe and effective rescue regimens for eradication failure of Helicobacter pylori infection by standard regimens is an urgent task. We designed the prospective study to compare the efficacy of two rescue regimens after eradication failure by the standard triple therapy.

METHODS

One hundred and thirty-two patients in whom eradication of H. pylori infection failed initial triple therapy with lansoprazole 30 mg b.i.d, amoxicillin 750 mg b.i.d. and clarithromycin 400 mg b.i.d. for 1 week were randomized to either the 1-week triple therapy with rabeprazole 10 mg b.i.d., amoxicillin 750 mg b.i.d., and metronidazole 250 mg b.i.d. (RAM) or the 2-week dual therapy with rabeprazole 10 mg q.i.d. and amoxicillin 500 mg q.i.d. (RA). Eradication of H. pylori was judged by (13)C-urea breath test 1 month later.

RESULTS

The intention-to-treat and per-protocol-based eradication rates were 92.4% (95% CI: 83.2-97.5) and 95.3% (95% CI: 86.9-99.0) for the RAM therapy and 90.9% (95% CI: 81.2-96.6) and 93.8% (95% CI: 84.8-98.3), respectively, for the RA therapy (P > 0.2 for both). No clinically recognizable adverse events were observed with either regimen.

CONCLUSION

RA as well as RAM therapy are safe and effective rescue regimens for H. pylori infection after eradication failure by the standard triple therapy.

摘要

背景与目的

针对标准疗法根除幽门螺杆菌感染失败的情况,开发安全有效的补救方案是一项紧迫任务。我们设计了这项前瞻性研究,以比较标准三联疗法根除失败后两种补救方案的疗效。

方法

132例患者初始采用兰索拉唑30 mg,每日2次、阿莫西林750 mg,每日2次、克拉霉素400 mg,每日2次的三联疗法治疗1周后,幽门螺杆菌感染根除失败,将其随机分为两组,一组接受雷贝拉唑10 mg,每日2次、阿莫西林750 mg,每日2次、甲硝唑250 mg,每日2次的1周三联疗法(RAM),另一组接受雷贝拉唑10 mg,每日4次、阿莫西林500 mg,每日4次的2周双联疗法(RA)。1个月后通过¹³C-尿素呼气试验判断幽门螺杆菌的根除情况。

结果

RAM疗法的意向性治疗和符合方案分析的根除率分别为92.4%(95%CI:83.2-97.5)和95.3%(95%CI:86.9-99.0),RA疗法分别为90.9%(95%CI:81.2-96.6)和93.8%(95%CI:84.8-98.3)(两者P均>0.2)。两种方案均未观察到临床上可识别的不良事件。

结论

对于标准三联疗法根除失败后的幽门螺杆菌感染,RA疗法和RAM疗法都是安全有效的补救方案。

相似文献

1
Dual therapy with high doses of rabeprazole and amoxicillin versus triple therapy with rabeprazole, amoxicillin, and metronidazole as a rescue regimen for Helicobacter pylori infection after the standard triple therapy.高剂量雷贝拉唑和阿莫西林联合治疗与雷贝拉唑、阿莫西林和甲硝唑三联疗法作为标准三联疗法后幽门螺杆菌感染的挽救方案。
Eur J Clin Pharmacol. 2007 Aug;63(8):743-9. doi: 10.1007/s00228-007-0302-8. Epub 2007 Jun 13.
2
High-dose rabeprazole-amoxicillin versus rabeprazole-amoxicillin-metronidazole as second-line treatment after failure of the Japanese standard regimen for Helicobacter pylori infection.高剂量雷贝拉唑-阿莫西林与雷贝拉唑-阿莫西林-甲硝唑作为幽门螺杆菌感染日本标准治疗方案失败后的二线治疗方案比较
Aliment Pharmacol Ther. 2003 Jul 1;18(1):101-7. doi: 10.1046/j.1365-2036.2003.01659.x.
3
Addition of metronidazole to rabeprazole-amoxicillin-clarithromycin regimen for Helicobacter pylori infection provides an excellent cure rate with five-day therapy.在雷贝拉唑-阿莫西林-克拉霉素方案中添加甲硝唑用于幽门螺杆菌感染的治疗,采用五日疗法可获得极佳的治愈率。
Helicobacter. 2000 Jun;5(2):88-93. doi: 10.1046/j.1523-5378.2000.00013.x.
4
Efficacy and tolerability of first-line triple therapy with levofloxacin and amoxicillin plus esomeprazole or rabeprazole for the eradication of Helicobacter pylori infection and the effect of CYP2C19 genotype: a 1-week, randomized, open-label study in Chinese adults.含左氧氟沙星、阿莫西林和埃索美拉唑或雷贝拉唑三联疗法一线治疗对幽门螺杆菌感染的根除效果和耐受性及 CYP2C19 基因型的影响:中国成年人为期 1 周的随机、开放标签研究。
Clin Ther. 2010 Nov;32(12):2003-11. doi: 10.1016/j.clinthera.2010.11.005.
5
Low-dose rabeprazole, amoxicillin and metronidazole triple therapy for the treatment of Helicobacter pylori infection in Chinese patients.低剂量雷贝拉唑、阿莫西林和甲硝唑三联疗法治疗中国患者幽门螺杆菌感染
J Gastroenterol Hepatol. 2005 Jun;20(6):935-40. doi: 10.1111/j.1440-1746.2005.03889.x.
6
Five-day proton pump inhibitor-based quadruple therapy regimen is more effective than 7-day triple therapy regimen for Helicobacter pylori infection.基于质子泵抑制剂的五日四联疗法方案在治疗幽门螺杆菌感染方面比七日三联疗法方案更有效。
Aliment Pharmacol Ther. 2001 Mar;15(3):417-21. doi: 10.1046/j.1365-2036.2001.00929.x.
7
Clinical outcomes of two-week sequential and concomitant therapies for Helicobacter pylori eradication: a randomized pilot study.两周序贯与同时疗法根除幽门螺杆菌的临床疗效:一项随机初步研究。
Helicobacter. 2013 Jun;18(3):180-6. doi: 10.1111/hel.12034. Epub 2013 Jan 11.
8
Concomitant therapy achieved the best eradication rate for Helicobacter pylori among various treatment strategies.在各种治疗策略中,联合治疗对幽门螺杆菌的根除率最高。
World J Gastroenterol. 2015 Jan 7;21(1):351-9. doi: 10.3748/wjg.v21.i1.351.
9
Efficacy of triple therapy comprising rabeprazole, amoxicillin and metronidazole for second-line Helicobacter pylori eradication in Japan, and the influence of metronidazole resistance.雷贝拉唑、阿莫西林和甲硝唑三联疗法在日本用于二线根除幽门螺杆菌的疗效及甲硝唑耐药性的影响。
Aliment Pharmacol Ther. 2003 Jan;17(1):119-23. doi: 10.1046/j.1365-2036.2003.01401.x.
10
Ten-day sequential versus triple therapy for Helicobacter pylori eradication: a prospective, open-label, randomized trial.十天序贯疗法与三联疗法治疗幽门螺杆菌根除:一项前瞻性、开放标签、随机试验。
J Gastroenterol Hepatol. 2012 Nov;27(11):1675-80. doi: 10.1111/j.1440-1746.2012.07249.x.

引用本文的文献

1
Should Metronidazole Be Included in Second-Line Treatment After Standard Triple Therapy for Helicobacter pylori?: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.幽门螺杆菌标准三联疗法后二线治疗中是否应包含甲硝唑?:随机对照试验的系统评价和荟萃分析
Helicobacter. 2025 Jan-Feb;30(1):e70010. doi: 10.1111/hel.70010.
2
Expectations for the Dual Therapy with Vonoprazan and Amoxicillin for the Eradication of .沃克帕唑与阿莫西林联合治疗根除幽门螺杆菌的预期疗效 。(你提供的原文似乎不完整,这里补充了合理内容使翻译更通顺)
J Clin Med. 2023 Apr 25;12(9):3110. doi: 10.3390/jcm12093110.
3
Dual therapy for Helicobacter pylori infection.

本文引用的文献

1
Third-line rescue therapy with levofloxacin is more effective than rifabutin rescue regimen after two Helicobacter pylori treatment failures.在两次幽门螺杆菌治疗失败后,左氧氟沙星三线挽救治疗比利福布汀挽救方案更有效。
Aliment Pharmacol Ther. 2006 Nov 15;24(10):1469-74. doi: 10.1111/j.1365-2036.2006.03149.x. Epub 2006 Oct 10.
2
Efficacy of metronidazole as second-line drug for the treatment of Helicobacter pylori Infection in the Japanese population: a multicenter study in the Tokyo Metropolitan Area.甲硝唑作为二线药物治疗日本人群幽门螺杆菌感染的疗效:东京都地区的一项多中心研究。
Helicobacter. 2006 Jun;11(3):152-8. doi: 10.1111/j.1523-5378.2006.00394.x.
3
幽门螺杆菌感染的双重治疗。
Chin Med J (Engl). 2023 Jan 5;136(1):13-23. doi: 10.1097/CM9.0000000000002565.
4
High-dose dual therapy culture-based susceptibility-guided therapy as a rescue regimen for infection: a randomized controlled trial.高剂量双重疗法 基于培养的药敏指导疗法作为感染的挽救方案:一项随机对照试验。
Therap Adv Gastroenterol. 2022 Dec 26;15:17562848221145566. doi: 10.1177/17562848221145566. eCollection 2022.
5
Efficacy and safety comparison of eradication between vonoprazan dual therapy triple therapy: a systematic review and meta-analysis.沃克帕唑双联疗法与三联疗法根除幽门螺杆菌的疗效和安全性比较:一项系统评价和荟萃分析
Therap Adv Gastroenterol. 2022 Oct 13;15:17562848221125308. doi: 10.1177/17562848221125308. eCollection 2022.
6
Allows Partial Patients to Avoid Reusing Bismuth Quadruple for Rescue Therapy: A Single-Center Randomized Controlled Study.允许部分患者避免重复使用铋四联进行挽救治疗:一项单中心随机对照研究。
Front Cell Infect Microbiol. 2022 Jul 8;12:903002. doi: 10.3389/fcimb.2022.903002. eCollection 2022.
7
Which is the best choice for eradication? Dual therapy or quadruple therapy?根除治疗的最佳选择是什么?双重疗法还是四联疗法?
Prz Gastroenterol. 2022;17(2):138-145. doi: 10.5114/pg.2022.116373. Epub 2022 May 19.
8
Culture-based antibiotic susceptibility testing for infection: a systematic review.基于培养的感染性疾病抗生素敏感性试验:一项系统评价
Ann Gastroenterol. 2022 Mar-Apr;35(2):127-134. doi: 10.20524/aog.2022.0689. Epub 2022 Feb 14.
9
diagnosis and therapy in the era of antimicrobial stewardship.抗菌药物管理时代的诊断与治疗
Therap Adv Gastroenterol. 2021 Dec 21;14:17562848211064080. doi: 10.1177/17562848211064080. eCollection 2021.
10
Cross-roads for meta-analysis and network meta-analysis of therapy.治疗的荟萃分析和网络荟萃分析的十字路口。
Gut. 2022 Mar;71(3):643-650. doi: 10.1136/gutjnl-2021-326170. Epub 2021 Nov 8.
Efficacy and safety of rifabutin-containing 'rescue therapy' for resistant Helicobacter pylori infection.
含利福布汀的“挽救疗法”用于耐药幽门螺杆菌感染的疗效与安全性。
Aliment Pharmacol Ther. 2006 Feb 15;23(4):481-8. doi: 10.1111/j.1365-2036.2006.02793.x.
4
Influence of CYP2C19 polymorphism and Helicobacter pylori genotype determined from gastric tissue samples on response to triple therapy for H pylori infection.通过胃组织样本确定的CYP2C19基因多态性和幽门螺杆菌基因型对幽门螺杆菌感染三联疗法疗效的影响。
Clin Gastroenterol Hepatol. 2005 Jun;3(6):564-73. doi: 10.1016/s1542-3565(04)00779-7.
5
Second-line treatment for Helicobacter pylori infection in Japan: proton pump inhibitor-based amoxicillin and metronidazole regimen.日本幽门螺杆菌感染的二线治疗:基于质子泵抑制剂的阿莫西林和甲硝唑疗法。
J Gastroenterol. 2004 Nov;39(11):1051-5. doi: 10.1007/s00535-004-1443-5.
6
Distribution of antibiotic MICs for Helicobacter pylori strains over a 16-year period in patients from Seoul, South Korea.韩国首尔患者幽门螺杆菌菌株16年间抗生素最低抑菌浓度的分布情况。
Antimicrob Agents Chemother. 2004 Dec;48(12):4843-7. doi: 10.1128/AAC.48.12.4843-4847.2004.
7
Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotype status.雷贝拉唑不同给药方案对夜间胃酸抑制作用与细胞色素P450 2C19基因分型状态的关系
Clin Pharmacol Ther. 2004 Oct;76(4):290-301. doi: 10.1016/j.clpt.2004.06.008.
8
Polymorphism of interleukin-1beta affects the eradication rates of Helicobacter pylori by triple therapy.白细胞介素-1β的多态性影响三联疗法根除幽门螺杆菌的比率。
Clin Gastroenterol Hepatol. 2004 Jan;2(1):22-30. doi: 10.1016/s1542-3565(03)00288-x.
9
In vitro post-antibiotic effect of fluoroquinolones, macrolides, beta-lactams, tetracyclines, vancomycin, clindamycin, linezolid, chloramphenicol, quinupristin/dalfopristin and rifampicin on Bacillus anthracis.氟喹诺酮类、大环内酯类、β-内酰胺类、四环素类、万古霉素、克林霉素、利奈唑胺、氯霉素、奎奴普丁/达福普汀及利福平对炭疽芽孢杆菌的体外抗生素后效应
J Antimicrob Chemother. 2004 Apr;53(4):609-15. doi: 10.1093/jac/dkh130. Epub 2004 Mar 3.
10
High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin.在使用常规剂量质子泵抑制剂、克拉霉素和阿莫西林的三联疗法根除幽门螺杆菌失败后,采用高剂量雷贝拉唑/阿莫西林疗法作为二线治疗方案。
Hepatogastroenterology. 2003 Nov-Dec;50(54):2274-8.